Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate

Journal of Diabetes

Volumn 7, Issue 1, 2015, Pages 41-46

  Kawasaki, Isao ^a   Hiura, Yoshikazu ^b   Tamai, Anna ^a   Yoshida, Yoko ^a   Yakusiji, Yosuke ^a   Ikuno, Yoshiko ^a   Okada, Megumi ^a   Ueno, Hiroki ^a   Tanaka, Nagaaki ^b   Yamagami, Keiko ^a   Fukumoto, Mariko ^a   Hosoi, Masayuki ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b Department of Internal Medicine   (Japan)

Author keywords

Albumin to creatinine ratio; Diabetic nephropathy; Sitagliptin

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; SITAGLIPTIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ALBUMIN URINE LEVEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LABORATORY TEST; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; URINALYSIS; ALBUMINURIA; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; URINE;

ALBUMINURIA; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 84920112253     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12153     Document Type: Article

References (15)

1. Viberti GC, Hill RD, Jarrett RJ etal. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982; 1: 1430-1432.
2. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984; 311: 89-93.
3. Araki S, Haneda M, Koya D etal. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007; 56: 1727-1730.
4. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS Group. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63: 225-232.
5. Schmieder RE, Mann JF, Schumacher H etal. ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol. 2011; 22: 1353-1364.
6. Augustyns K, Bal G, Thonus G etal. The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem. 1999; 6: 311-327.
7. Pala L, Mannucci E, Pezzatini A etal. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun. 2003; 310: 28-31.
8. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelation of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: A streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol. 2008; 200: 53-61.
9. Mega C, de Lemos ET, Vala H etal. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker Diabetic Fatty Rat). Exp Diabetes Res. 2011; 2011: 1-12.
10. Seino Y, Nanjo K, Tajima N etal. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest. 2010; 1: 212-228.
11. Kashiwagi A, Kasuga M, Araki E etal. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012; 3: 39-40.
12. Mistry GC, Maes AL, Lasseter KC etal. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008; 48: 592-598.
13. Ogawa S, Ishiki M, Nako K etal. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011; 223: 133-135.
14. Gutzwiller JP, Tschopp S, Bock A etal. Glucagon-like peptide 1 induces natriuresis in healthy subjects and insulin-resistant obese men. J Clin Endocrinol Metab. 2004; 89: 3055-3061.
15. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011; 58: 69-73.